<div id="readability-page-1"><p>Federated Hermes Inc. boosted its stake in shares of  Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 3,104.3% during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor  owned 99,814 shares of the company's stock after purchasing an additional 96,699 shares during the period. Federated Hermes Inc. owned about 0.27% of Entrada Therapeutics worth $1,726,000 at the end of the most recent reporting period.</p><div><p><span></span><span>Get <strong>Entrada Therapeutics</strong> alerts:</span></p></div><ul><li>Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings</li></ul><p>Several other large investors have also recently added to or reduced their stakes in TRDA. Vanguard Group Inc. grew its stake in shares of  Entrada Therapeutics by 19.7% in the 4th quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company's stock valued at $25,317,000 after buying an additional 241,052 shares in the last quarter.  Geode Capital Management LLC grew its position in  Entrada Therapeutics by 8.8% in the third quarter. Geode Capital Management LLC now owns 576,451 shares of the company's stock worth $9,214,000 after acquiring an additional 46,512 shares in the last quarter.  State Street Corp grew its position in  Entrada Therapeutics by 5.5% in the third quarter. State Street Corp now owns 469,601 shares of the company's stock worth $7,504,000 after acquiring an additional 24,385 shares in the last quarter.  Arrowstreet Capital Limited Partnership increased its stake in shares of  Entrada Therapeutics by 123.2% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company's stock worth $3,847,000 after purchasing an additional 122,823 shares during the last quarter.  Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of  Entrada Therapeutics by 6.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company's stock valued at $3,408,000 after purchasing an additional 11,143 shares in the last quarter. Institutional investors and hedge funds own  86.39% of the company's stock. </p><h2>Entrada Therapeutics Stock Up 0.3 %</h2><p>Shares of Entrada Therapeutics stock opened at $7.92 on Tuesday. Entrada Therapeutics, Inc. has a 12-month low of $7.10 and a 12-month high of $21.79. The stock has a 50 day moving average price of $10.69 and a two-hundred day moving average price of $14.81. The stock has a market capitalization of $297.75 million, a P/E ratio of 4.98 and a beta of 0.04. </p><p>Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last posted its earnings results on Thursday, February 27th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.66) by $0.69. The business had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%.  Sell-side analysts anticipate that  Entrada Therapeutics, Inc. will post 1.12 earnings per share for the current year. </p><h2>Wall Street Analyst Weigh In</h2><p>Separately, HC Wainwright  reiterated a &#34;buy&#34; rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a report on Monday, March 31st.</p><p><b>View Our Latest Analysis on Entrada Therapeutics</b></p><h2>About Entrada Therapeutics</h2> (Free Report)<p>Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Entrada Therapeutics</li><li>How to start investing in penny stocks</li><li>Why NVIDIA Stock Could Soar Despite Wall Street Downgrades</li><li>How to Read Stock Charts for Beginners</li><li>Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold</li><li>Insider Buying Explained: What Investors Need to Know</li><li>3 Hot New IPOs Defying the 2025 Market Slump</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJEQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFJEQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Entrada Therapeutics Right Now?</h2><p>Before you consider Entrada Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entrada Therapeutics wasn't on the list.</p><p>While Entrada Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TRDA

<p>Federated Hermes Inc. significantly increased its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 3,104.3% in Q4, owning 99,814 shares valued at $1.73 million. Other investors like Vanguard and Geode Capital also raised their stakes. Entrada's stock opened at $7.92, with a 12-month range of $7.10 to $21.79. The company reported a positive EPS of $0.03, exceeding estimates, and analysts predict an EPS of 1.12 for the current year. HC Wainwright maintains a "buy" rating with a $20 price target.</p>

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Holdings Increased by Federated Hermes Inc.